Agilent collaborates to identify causes of outbreaks
Agilent (Santa Clara, California, USA), The U.S. Food and Drug Administration, the University of California, Davis, California, USA, and the Centres for Disease Control and Prevention have announced a collaboration to create a public database of 100,000 foodborne pathogen genomes to help speed identification of bacteria responsible for foodborne outbreaks.
Agilent (Santa Clara, California, USA), The U.S. Food and Drug Administration, the University of California, Davis, California, USA, and the Centres for Disease Control and Prevention have announced a collaboration to create a public database of 100,000 foodborne pathogen genomes to help speed identification of bacteria responsible for foodborne outbreaks.
Called the 100K Genome Project, the collaboration will be a five-year project to sequence the genetic code of important foodborne pathogens and make this information available in a free, public database. The sequencing will include the genomes of pathogens such as salmonella, listeria and E. coli.
Open access to the database will allow researchers to develop tests that can identify the type of bacteria present in a sample within a matter of days or hours, significantly faster than the approximately one week it now takes between diagnosis and genetic analysis.
Agilent is providing scientific expertise, instrumentation and funding to support a part of the University of California’s activities.
Mike McMullen, president of Agilent's Chemical Analysis Group, said, "Each year in the United States there are more than 48 million cases of foodborne illness. A problem of this magnitude demands an equally large countermeasure. We see this project as a way to improve quality of life for a great many people, while minimizing a major business risk for food producers and distributors."
For more information please visit ref="http://www.agilent.com">www.agilent.com
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
